|
1
|
Sorlie T, Perou CM, Tibshirani R, et al:
Gene expression patterns of breast carcinomas distinguish tumor
subclasses with clinical implications. Proc Natl Acad Sci USA.
98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Di Leva G and Croce CM: Roles of small
RNAs in tumor formation. Trends Mol Med. 16:257–267. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lowery AJ, Miller N, Devaney A, et al:
MicroRNA signatures predict oestrogen receptor, progesterone
receptor and HER2/ neu receptor status in breast cancer. Breast
Cancer Res. 11:R272009. View
Article : Google Scholar
|
|
4
|
Gasparini P, Cascione L, Fassan M, et al:
microRNA expression profiling identifies a four microRNA signature
as a novel diagnostic and prognostic biomarker in triple negative
breast cancers. Oncotarget. 5:1174–1184. 2014.PubMed/NCBI
|
|
5
|
Buffa FM, Camps C, Winchester L, et al:
microRNA-associated progression pathways and potential therapeutic
targets identified by integrated mRNA and microRNA expression
profiling in breast cancer. Cancer Res. 71:5635–5645. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Iorio MV, Ferracin M, Liu CG, et al:
MicroRNA gene expression deregulation in human breast cancer.
Cancer Res. 65:7065–7070. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cochrane DR, Cittelly DM, Howe EN, et al:
MicroRNAs link estrogen receptor alpha status and Dicer levels in
breast cancer. Horm Cancer. 1:306–319. 2010. View Article : Google Scholar
|
|
8
|
Foekens JA, Sieuwerts AM, Smid M, et al:
Four miRNAs associated with aggressiveness of lymph node-negative,
estrogen receptor-positive human breast cancer. Proc Natl Acad Sci
USA. 105:13021–13026. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH,
Ambs S and Caplen NJ: Identification of the receptor tyrosine
kinase AXL in breast cancer as a target for the human miR-34a
microRNA. Breast Cancer Res Treat. 130:663–679. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Janssen EA, Slewa A, Gudlaugsson E, et al:
Biologic profiling of lymph node negative breast cancers by means
of microRNA expression. Mod Pathol. 23:1567–1576. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
de Rinaldis E, Gazinska P, Mera A, et al:
Integrated genomic analysis of triple-negative breast cancers
reveals novel microRNAs associated with clinical and molecular
phenotypes and sheds light on the pathways they control. BMC
Genomics. 14:6432013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Calvano Filho CM, Calvano-Mendes DC,
Carvalho KC, et al: Triple-negative and luminal breast tumors:
differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p.
Tumour Biol. 35:7733–7741. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Farazi TA, Ten Hoeve JJ, Brown M, et al:
Identification of distinct miRNA target regulation between breast
cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets.
Genome Biol. 15:R92014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nassirpour R, Mehta PP, Baxi SM and Yin
MJ: miR-221 promotes tumorigenesis in human triple negative breast
cancer cells. PLoS One. 8:e621702013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sharma SB, Lin CC, Farrugia MK, et al:
microRNAs-206 and -21 cooperate to promote RAS-ERK signaling by
suppressing the translation of RASA1 and SPRED1. Mol Cell Biol.
34:4143–4164. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dong G, Liang X, Wang D, et al: High
expression of miR-21 in triple-negative breast cancers was
correlated with a poor prognosis and promoted tumor cell in vitro
proliferation. Med Oncol. 31:572014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang C, Zheng X, Shen C and Shi Y:
MicroRNA-203 suppresses cell proliferation and migration by
targeting BIRC5 and LASP1 in human triple-negative breast cancer
cells. J Exp Clin Cancer Res. 31:582012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Taylor MA, Sossey-Alaoui K, Thompson CL,
Danielpour D and Schiemann WP: TGF-beta upregulates miR-181a
expression to promote breast cancer metastasis. J Clin Invest.
123:150–163. 2013. View
Article : Google Scholar :
|
|
19
|
Gregory PA, Bert AG, Paterson EL, et al:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Howe EN, Cochrane DR and Richer JK:
Targets of miR-200c mediate suppression of cell motility and
anoikis resistance. Breast Cancer Res. 13:R452011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cascione L, Gasparini P, Lovat F, et al:
Integrated microRNA and mRNA signatures associated with survival in
triple negative breast cancer. PLoS One. 8:e559102013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Avery-Kiejda KA, Braye SG, Mathe A, Forbes
JF and Scott RJ: Decreased expression of key tumour suppressor
microRNAs is associated with lymph node metastases in triple
negative breast cancer. BMC Cancer. 14:512014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang J, Tsouko E, Jonsson P, et al:
miR-206 inhibits cell migration through direct targeting of the
actin-binding protein Coronin 1C in triple-negative breast cancer.
Mol Oncol. 8:1690–1702. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Eades G, Wolfson B, Zhang Y, Li Q, Yao Y
and Zhou Q: lincRNA-RoR and miR-145 regulate invasion in
triple-negative breast cancer via targeting ARF6. Mol Cancer Res.
Sep 24–2014.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Humphries B, Wang Z, Oom AL, et al:
MicroRNA-200b targets protein kinase Calpha and suppresses
triple-negative breast cancer metastasis. Carcinogenesis.
35:2254–2263. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee ST, Feng M, Wei Y, et al: Protein
tyrosine phosphatase UBASH3B is overexpressed in triple-negative
breast cancer and promotes invasion and metastasis. Proc Natl Acad
Sci USA. 110:11121–11126. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jin L, Lim M, Zhao S, et al: The
metastatic potential of triple-negative breast cancer is decreased
via caloric restriction-mediated reduction of the miR-17~92
cluster. Breast Cancer Res Treat. 146:41–50. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu H, Wang Y, Li X, et al: Expression and
regulatory function of miRNA-182 in triple-negative breast cancer
cells through its targeting of profilin 1. Tumour Biol.
34:1713–1722. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Toyama T, Kondo N, Endo Y, et al: High
expression of microRNA-210 is an independent factor indicating a
poor prognosis in Japanese triple-negative breast cancer patients.
Jpn J Clin Oncol. 42:256–263. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kong W, He L, Richards EJ, et al:
Upregulation of miRNA-155 promotes tumour angiogenesis by targeting
VHL and is associated with poor prognosis and triple-negative
breast cancer. Oncogene. 33:679–689. 2014. View Article : Google Scholar :
|
|
31
|
Shen S, Sun Q, Liang Z, et al: A
prognostic model of triple-negative breast cancer based on
miR-27b-3p and node status. PLoS One. 9:e1006642014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Svoboda M, Sana J, Redova M, et al:
MiR-34b is associated with clinical outcome in triple-negative
breast cancer patients. Diagn Pathol. 7:312012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Radojicic J, Zaravinos A, Vrekoussis T,
Kafousi M, Spandidos DA and Stathopoulos EN: MicroRNA expression
analysis in triple-negative (ER, PR and Her2/neu) breast cancer.
Cell Cycle. 10:507–517. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Deng X, Cao M, Zhang J, et al: Hyaluronic
acid-chitosan nanoparticles for co-delivery of miR-34a and
doxorubicin in therapy against triple negative breast cancer.
Biomaterials. 35:4333–4344. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tan X, Peng J, Fu Y, et al: miR-638
mediated regulation of BRCA1 affects DNA repair and sensitivity to
UV and cisplatin in triple negative breast cancer. Breast Cancer
Res. 16:4352014. View Article : Google Scholar
|
|
36
|
Bisso A, Faleschini M, Zampa F, et al:
Oncogenic miR-181a/b affect the DNA damage response in aggressive
breast cancer. Cell Cycle. 12:1679–1687. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Polytarchou C, Iliopoulos D and Struhl K:
An integrated transcriptional regulatory circuit that reinforces
the breast cancer stem cell state. Proc Natl Acad Sci USA.
109:14470–14475. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ahmad A, Sarkar SH, Bitar B, et al:
Garcinol regulates EMT and Wnt signaling pathways in vitro and in
vivo, leading to anti-cancer activity against breast cancer cells.
Mol Cancer Ther. 11:2193–2201. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Si L, Jiang F, Li Y, et al: Induction of
the mesenchymal to epithelial transition by demethylation-activated
microRNA-200c is involved in the anti-migration/invasion effects of
arsenic trioxide on human breast cancer cells. Mol Carcinog. Apr
14–2014.(Epub ahead of print). View
Article : Google Scholar
|
|
40
|
Johansson J, Berg T, Kurzejamska E, et al:
MiR-155-mediated loss of C/EBPbeta shifts the TGF-beta response
from growth inhibition to epithelial-mesenchymal transition,
invasion and metastasis in breast cancer. Oncogene. 32:5614–5624.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Aceto N, Sausgruber N, Brinkhaus H, et al:
Tyrosine phosphatase SHP2 promotes breast cancer progression and
maintains tumor-initiating cells via activation of key
transcription factors and a positive feedback signaling loop. Nat
Med. 18:529–537. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
42
|
Augoff K, McCue B, Plow EF and
Sossey-Alaoui K: miR-31 and its host gene lncRNA LOC554202 are
regulated by promoter hypermethylation in triple-negative breast
cancer. Mol Cancer. 11:52012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Krishnan K, Steptoe AL, Martin HC, et al:
miR-139-5p is a regulator of metastatic pathways in breast cancer.
RNA. 19:1767–1780. 2013. View Article : Google Scholar : PubMed/NCBI
|
